Panacea secures $15m financing for Phase 1 clinical study of cancer immunotherapeutic drug
The company has also secured an additional $2 million optional financing commitment in this series. Panacea Pharmaceuticals chairman & CEO/CSO Hossein Ghanbari said: "Our lead drug candidate, our